Sanofi (NASDAQ:SNY) Given Consensus Rating of “Hold” by Brokerages

Sanofi (NASDAQ:SNY) has been given a consensus rating of “Hold” by the fifteen research firms that are presently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a hold rating, three have issued a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $51.00.

Several equities research analysts recently issued reports on the company. Morgan Stanley set a $52.00 price objective on Sanofi in a report on Friday, May 1st. Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Monday, April 20th. Finally, Citigroup restated a “neutral” rating on shares of Sanofi in a report on Monday, April 13th.

Institutional Investors Weigh In On Sanofi

Several large investors have recently bought and sold shares of the stock. Advisory Services Network LLC increased its holdings in Sanofi by 1.4% during the 3rd quarter. Advisory Services Network LLC now owns 15,733 shares of the company’s stock worth $743,000 after purchasing an additional 210 shares during the period. Savant Capital LLC increased its holdings in Sanofi by 2.7% during the 4th quarter. Savant Capital LLC now owns 8,623 shares of the company’s stock worth $418,000 after purchasing an additional 225 shares during the period. Wesbanco Bank Inc. increased its holdings in Sanofi by 4.9% during the 4th quarter. Wesbanco Bank Inc. now owns 4,927 shares of the company’s stock worth $239,000 after purchasing an additional 230 shares during the period. IFG Advisory LLC increased its holdings in Sanofi by 2.7% during the 4th quarter. IFG Advisory LLC now owns 9,213 shares of the company’s stock worth $446,000 after purchasing an additional 244 shares during the period. Finally, Cohen Investment Advisors LLC increased its holdings in Sanofi by 2.9% during the 1st quarter. Cohen Investment Advisors LLC now owns 9,480 shares of the company’s stock worth $457,000 after purchasing an additional 263 shares during the period. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Sanofi Price Performance

SNY stock opened at $44.25 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $107.28 billion, a PE ratio of 12.36, a P/E/G ratio of 1.09 and a beta of 0.34. Sanofi has a 12-month low of $42.28 and a 12-month high of $52.68. The business’s fifty day moving average price is $45.14 and its 200 day moving average price is $46.55.

Sanofi Increases Dividend

The business also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were issued a dividend of $2.4225 per share. This is a positive change from Sanofi’s previous annual dividend of $2.04. The ex-dividend date was Monday, May 4th. This represents a yield of 559.0%. Sanofi’s dividend payout ratio (DPR) is currently 49.16%.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.